OnKure gets FDA nod to start clinical trials
BOULDER — OnKure Inc., a Boulder-based developer of cancer therapies, has been given the go-ahead by the U.S. Food and Drug Administration to begin phase one clinical trials for the company’s lead drug OKI-179.
“OnKure’s platform is capable of transforming naturally occurring, biologically active lead compounds into commercial drugs that address a variety of diseases, with an emphasis on helping patients suffering from cancer,” according to a company news release.
OnKure is collaborating with the University of Colorado’s Anschutz Cancer Center and the University of Texas’s Dell Medical School on the clinical trial.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Downtown Boulder’s Business Improvement District is recruiting two at-large board members.
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
The Nest Schools will continue its expansion in Colorado with its seventh location set to…
